×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
OTCMKTS:XSNX

NovAccess Global Stock Forecast, Price & News

$0.15
-0.03 (-15.01%)
(As of 06/24/2022 02:15 PM ET)
Add
Compare
Today's Range
$0.15
$0.25
50-Day Range
$0.10
$0.48
52-Week Range
$0.10
$0.96
Volume
7,501 shs
Average Volume
4,652 shs
Market Capitalization
$2.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive XSNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovAccess Global and its competitors with MarketBeat's FREE daily newsletter.

XSNX Stock Forecast (MarketRank)

Overall MarketRank

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
NovAccess Global logo

About NovAccess Global (OTCMKTS:XSNX)

NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. The company specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. NovAccess Global Inc. was incorporated in 1997 and is headquartered in Chesterland, Ohio.

XSNX Stock News Headlines

NovAccess Global CEO Dwain Irvin Featured on MoneyTV
This Week on MoneyTV with Donald Baillargeon, 6/10
NovAccess Global (OTCMKTS:XSNX) Trading 47.2% Higher
See More Headlines

Industry, Sector and Symbol

Industry
Unsupported plastics film & sheet
Sub-Industry
N/A
Current Symbol
OTCMKTS:XSNX
Employees
2
Year Founded
N/A

Company Calendar

Today
6/24/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
9/30/2022

Profitability

Net Income
$-2.51 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.62) per share

Miscellaneous

Free Float
18,134,000
Market Cap
$2.76 million
Optionable
Not Optionable
Beta
1.57














NovAccess Global Frequently Asked Questions

How has NovAccess Global's stock price performed in 2022?

NovAccess Global's stock was trading at $0.3550 at the beginning of 2022. Since then, XSNX stock has decreased by 57.7% and is now trading at $0.1501.
View the best growth stocks for 2022 here
.

When is NovAccess Global's next earnings date?

NovAccess Global is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for NovAccess Global
.

Who are NovAccess Global's key executives?

NovAccess Global's management team includes the following people:
  • Dr. Dwain K. Morris-Irvin M.P.H., MPH, Ph.D., Chief Exec. Officer (Age 54, Pay $233.49k)
  • Mr. Neil J. Laird, Chief Financial Officer (Age 69)
  • Dr. Christopher Wheeler Ph.D., Pres of Stemvax Therapeutics

Who are some of NovAccess Global's key competitors?

What other stocks do shareholders of NovAccess Global own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovAccess Global investors own include Co-Diagnostics (CODX), iBio (IBIO), PharmaCyte Biotech (PMCB), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Kopin (KOPN), Ascent Solar Technologies (ASTI) and BioRestorative Therapies (BRTX).

What is NovAccess Global's stock symbol?

NovAccess Global trades on the OTCMKTS under the ticker symbol "XSNX."

How do I buy shares of NovAccess Global?

Shares of XSNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovAccess Global's stock price today?

One share of XSNX stock can currently be purchased for approximately $0.15.

How much money does NovAccess Global make?

NovAccess Global (OTCMKTS:XSNX) has a market capitalization of $2.76 million.

How many employees does NovAccess Global have?

NovAccess Global employs 2 workers across the globe.

How can I contact NovAccess Global?

NovAccess Global's mailing address is 8834 MAYFIELD RD, CHESTERLAND OH, 44026. The official website for NovAccess Global is www.xsunx.com. The company can be reached via phone at (440) 644-1027, via email at [email protected], or via fax at 949-266-5823.

This page (OTCMKTS:XSNX) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.